Quang X. Pham
Known title: CEO and ChairmanCIK: 0001405290
Quang X. Pham's purchase track record
Quang X. Pham has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/1/2023 | CVKD | $100K | -43.9% | -22.3% | +13.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CVKD | ▼ Sell | Open Market | 7,400 | $22K | 6/29/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 9,029 | $28K | 6/26/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 2,127 | $6K | 6/25/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 2,277 | $7K | 6/23/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 9,167 | $33K | 6/22/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 513 | $2K | 6/17/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 3,613 | $11K | 6/16/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 3,666 | $13K | 6/15/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 12,996 | $51K | 6/12/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,462 | $6K | 6/11/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 3,500 | $15K | 6/10/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 12,992 | $53K | 6/9/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 5,893 | $26K | 6/8/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 2,064 | $9K | 6/5/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 3,898 | $17K | 6/4/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 2,323 | $10K | 6/3/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 349 | $2K | 6/2/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 303 | $2K | 5/29/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 2,989 | $15K | 5/28/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,165 | $7K | 5/22/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 3,298 | $17K | 5/12/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 6,476 | $37K | 5/11/2026 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,315 | $18K | 10/27/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,129 | $16K | 10/24/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,800 | $25K | 10/13/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,800 | $25K | 10/9/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 500 | $7K | 10/2/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 881 | $12K | 10/1/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 419 | $6K | 9/29/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 6,790 | $96K | 9/25/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 2,581 | $36K | 9/24/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,193 | $17K | 8/28/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 3,836 | $54K | 8/27/2025 | View on chart |
| CVKD | ▼ Sell | Gift | 50,000 | $0 | 4/10/2024 | View on chart |
| CVKD | ▼ Sell | Gift | 85,000 | $0 | 10/23/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 20,000 | $18K | 9/5/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 20,000 | $18K | 9/5/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 10,000 | $9K | 9/1/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 20,000 | $19K | 9/1/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 20,000 | $18K | 9/1/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 10,000 | $9K | 9/1/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 10,000 | $8K | 9/1/2023 | View on chart |
| CVKD | ▲ Buy | Grant | 25,000 | $49K | 2/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Cadrenal hires Tungsten Advisors to drive strategic process
Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.
Cadrenal hires Tungsten Advisors to drive strategic process. Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.